Does Retinoic Acid Reverse Cell Cycle Dysregulation in Alzheimer's Disease Lymphocytes?

Asian J Psychiatr. 2019 Jan;39:174-177. doi: 10.1016/j.ajp.2018.08.010. Epub 2018 Aug 16.

Abstract

Aberrant re-entry of neurons into cell cycle appears to be an early event in Alzheimer's disease (AD) and targeting this dysregulation may have therapeutic potential. We have examined whether cell cycle dysregulation in AD can be detected using patient and control derived B-lymphocytes. Cell cycle analysis using flow cytometry demonstrated that cell cycle dysregulation occurs in AD lymphocytes, with a significant difference in the distribution of cells in G0/G1, S and G2/M phases of cell cycle as compared to control lymphocytes. Using global gene expression analysis by RNA sequencing and cell cycle analysis, we examined the role of Retinoic Acid (RA), a candidate molecule predicted to be of therapeutic potential in cell cycle dysregulation associated with AD. CCND1, CCNE2, E2F transcription factors which are known to be dysregulated in AD were among the 32 genes that showed differential expression in response to RA treatment thus suggesting a protective role of RA. However, the cell cycle analysis demonstrated that RA did not reverse the cellular phenotype in AD lymphocytes. This suggests that though RA might have a protective role by influencing the expression of cell cycle genes, it might not be able to arrest abnormal re-entry into cell cycle.

Keywords: Alzheimer’s disease; B-lymphocytes; Cell cycle; Dysregulation; Genes; Retinoic acid.

MeSH terms

  • Aged
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / physiopathology*
  • Cell Cycle / drug effects*
  • Flow Cytometry
  • Humans
  • Lymphocytes / drug effects
  • Lymphocytes / metabolism*
  • Tretinoin / pharmacology*

Substances

  • Tretinoin